Download PDF
Dtsch Med Wochenschr 2021; 146(09): 613-617
DOI: 10.1055/a-1066-8894
Schritt für Schritt

Vorhofohrverschluss – Schritt für Schritt

Left Atrial Appendage Closure – step by step
Kolja Sievert
,
Stefan Bertog
,
Horst Sievert
› Further Information
Also available at
    Permissions and Reprints

Thromben im linken Vorhofohr infolge von Vorhofflimmern sind die häufigste Ursache embolischer Schlaganfälle [1]. Antikoagulanzien sind eine wirksame Prophylaxe [2]. Patienten mit nicht-valvulärem Vorhofflimmern mit Kontraindikationen gegen eine Antikoagulation können von einem Vorhofohrverschluss profitieren [3].

Abstract

Thrombus formation due to atrial fibrillation is the most common cause of embolic stroke. Anticoagulation offers an effective prophylaxis. However, anticoagulation in turn has an inherent increased risk of bleeding. Patients with non-valvular atrial fibrillation who have contraindications for anticoagulation may profit from a closure of the left atrial appendage. The most commonly and best studied devices for this are the WATCHMAN™ and the AMPLATZER Amulet™ Occluders.

In this How-To article, the aim is to offer a general overview of the indications, contraindications and complications as well as the implantation and postoperative management of patients receiving LAA closure by example of the WATCHMAN FLX™ Occluder.

Schlüsselwörter

Vorhofflimmern - Okkluder - Antikoagulation - Restleck - TEE

Key words

atrial fibrillation - occluder - anticoagulation - leakage - TEE


Publication History

Article published online:
30 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Michel P, Odier C, Faouzi M. et al. The Acuts STroke Registry and Analysis of Lausanne (ASTRAL). Stroke 2010; 41: 2491-2498
    CrossrefPubMedGoogle Scholar
  • 2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
    CrossrefPubMedGoogle Scholar
  • 3 Holmes Jr DR, Doshi SK, Kar S. et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015; 65: 2614-2623
    CrossrefPubMedGoogle Scholar
  • 4 Glikson M, Wolff R, Hindricks G. et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update. EuroIntervention 2020; 15: 1133-1180
    CrossrefPubMedGoogle Scholar
  • 5 Holmes DR, Reddy VY, Turi ZG. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542
    CrossrefPubMedGoogle Scholar
  • 6 Reddy VY, Gibson DN, Kar S. et al. Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol 2017; 69: 253-261
    CrossrefPubMedGoogle Scholar
  • 7 Boersma LV, Schmidt B, Betts TR. et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 2016; 37: 2465-2474
    CrossrefPubMedGoogle Scholar
  • 8 Sondergaard L, Wong Y-H, Reddy VY. et al Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With Watchman. JACC Cardiovasc Interv 2019; 12: 1055-1063
    CrossrefPubMedGoogle Scholar
  • 9 Reddy VY, Doshi SK, Kar S. et al. 5-Year outcomes after left atrial appendage closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017; 70: 2964-2975
    CrossrefPubMedGoogle Scholar
  • 10 Osmancik O, Tousek P, Herman D. et al Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study). Am Heart J 2017; 183: 108-114
    CrossrefPubMedGoogle Scholar